Premium
Dendritic Cells in Bone Marrow at Diagnosis and after Chemotherapy in Adult Patients with Acute Myeloid Leukaemia
Author(s) -
Derolf Å. R.,
Laane E.,
Björklund E.,
Saft L.,
Björkholm M.,
Porwit Anna
Publication year - 2014
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/sji.12223
Subject(s) - bone marrow , medicine , immunophenotyping , chemotherapy , minimal residual disease , myeloid , haematopoiesis , flow cytometry , dendritic cell , immunology , gastroenterology , antigen , stem cell , biology , genetics
Dendritic cells (DCs) develop in the bone marrow from haematopoietic progenitor cells. Two subsets, plasmacytoid DC s (p DC s) and myeloid DC s (m DC s), have been identified. Little is known regarding DC levels in bone marrow of patients with acute myeloid leukaemia ( AML ) before and after chemotherapy. We investigated relative p DC and m DC levels in bone marrow from 37 hospital controls and 60 patients with AML [at diagnosis, complete remission ( CR ) and follow‐up] using four‐colour flow cytometry. The p DC immunophenotype was characterized as lin‐/HLA‐DR+/CD123 + and m DC as lin‐/ HLA ‐ DR +/ CD 11c+. In 69% of patients with AML , no DC s were detected at diagnosis. At CR , m DC levels were the same in patients with AML and hospital controls while p DC levels were slightly lower. There was no association between minimal residual disease or survival rates and DC levels. Patients with low m DC levels at CR were more likely to suffer from complicated infections, although the difference was not statistically significant. Altogether, there was a profound decrease in DC levels in patients with AML at diagnosis. DC levels increased at CR and were higher than in hospital controls after post‐remission therapy, suggesting that DC s recover after repeated chemotherapy. There may be an association between m DC levels and infectious complications.